Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab Phase I in Active GPP
NCT02978690Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2016
- Primary completion
- Sep 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Patients With Adverse Reactions, Defined as Drug-related Adverse Events up to 140 days. Started Dec 2016; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT02978690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978690.